Skip to main content
    C

    Celldex Therapeutics Inc (CLDX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $28.59
    -0.24 (-0.83%)

    Market Cap: $2.26B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Celldex Therapeutics Inc (CLDX) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Celldex Therapeutics (CLDX) to earn -$4.02 per share in the fiscal year ending Dec 31, 2026, on revenue of $1.37M. Of 15 analysts, 14 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. For the fiscal year ending Dec 31, 2027, the EPS consensus is -$4.19.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 15 ratings average 1.93, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 93% of the ratings.

    RatingAnalystsShare
    Strong Buy213.3%
    Buy1280.0%
    Hold16.7%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    15

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus shows a larger loss and revenue estimates rise 383.2%.

    Fiscal year ending Dec 31, 2026
    -$4.02
    EPS consensus, revenue $1.37M
    Fiscal year ending Dec 31, 2027
    -$4.19
    EPS consensus, revenue $6.62M
    Next report
    Feb 23, 2027
    Estimated

    EPS range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$4.02-$4.14 to -$3.658$1.37MN/A10
    Dec 31, 2027-$4.19-$4.87 to -$3.4710$6.62MN/A10

    Quarterly Estimates

    The EPS consensus rises from -$1.06 for the quarter ending Dec 31, 2026 to -$0.97 for the quarter ending Mar 31, 2027.

    EPS range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$1.06-$1.10 to -$0.9715$1.73MN/A13
    Mar 31, 2027-$0.97-$1.14 to -$0.815$250000N/A4

    Estimate Revisions

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202702

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$4.11.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$4.02-$4.12-$4.12-$4.12-$4.11N/A
    Fiscal year ending Dec 31, 2027-$4.19-$4.25-$4.24-$4.21-$4.16N/A
    Quarter ending Mar 31, 2027-$0.97-$0.91-$0.91-$0.91-$0.91N/A

    Frequently Asked Questions About CLDX

    What is the CLDX stock forecast?

    Consensus analyst estimates put Celldex Therapeutics's EPS at -$4.02 for the fiscal year ending Dec 31, 2026, on revenue of $1.37M. The consensus rating from 15 analysts is Buy.

    How do analysts rate CLDX stock?

    Of 15 analysts covering Celldex Therapeutics, 2 rate it Strong Buy, 12 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from CLDX next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$4.02, with estimates from -$4.14 to -$3.65 from 8 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$4.19, with estimates from -$4.87 to -$3.47 from 10 analysts.

    What revenue do analysts expect from Celldex Therapeutics next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $1.37M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $6.62M.

    How many analysts cover CLDX?

    15 analysts rate Celldex Therapeutics stock, and 8 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.